Scandion Oncology () | Spotlight

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

Bo Rode Hansen

Chairperson of the Board

Peter Høngaard

Board

Annie Rasmussen
Bo Hansen
Carl Borrebäck
Christian Vinding Thomsen
Jørgen Bardenfleth
Thomas Feldthus

Articles of association

News

2021-01-28 21:35:07 Scandion Oncology adjusts the PANTAX pancreatic cancer study
2021-01-23 13:40:56 Scandion Oncology has finalized the first 12 patients in the CORIST study
2021-01-19 16:53:53 Spotlight: Market Notice 11/21 - Scandion Oncology A/S will be delisted after close of the market on February 2, 2021
2021-01-19 15:34:24 Scandion Oncology approved for listing on Nasdaq First North Growth Market Sweden on 3 February 2021
2021-01-07 08:53:33 Spotlight: Market Notice 5/21– Last day of trading in Scandion Oncology A/S’s BTA

Show More

Analysis

2018-10-09 SvD Börsplus: Svår att motstå?

Videos

Largest Owners

Name	Capital %	Votes %	Date
Dan Peters	18,40	18,40	2025-05-27
Avanza Pension	7,31	7,31	2025-05-27

Annual reports, prospectus etc.